Researchers will highlight results from the LENS trial and the efficacy of fenofibrate in the treatment of diabetic retinopathy in a Friday, June 21, symposium.
Systemic Medications for Diabetic Retinopathy—Protective and Risk Factors will take place from 3:45 p.m. – 5:15 p.m. ET in Room W208 of the Orange County Convention Center. The session will be available on-demand on the virtual meeting platform for registered meeting participants following the 84th Scientific Sessions.
Fenofibrate has been used to lower cholesterol for more than three decades, and research suggests the drug may delay the progression of diabetic retinopathy, which is one of the main causes of blindness and poor vision among working-age adults.
More than 1,000 people with diabetes and retinopathy are participating in Lowering Events in Non-proliferative Retinopathy in Scotland (LENS), which is investigating the effects of fenofibrate on diabetic retinopathy progression.
David Preiss, MBChB, MRCP, FRCPath, PhD, University of Oxford, United Kingdom, will present LENS results.
The symposium also will include information on the role of systemic pharmacotherapy in the prevention and management of diabetic macular edema from Andrew J. Barkmeier, MD, Mayo Clinic.
Alicia Jenkins, MBBS, MD, FRACP, FRCP, Baker Heart and Diabetes Institute, will share data from the FAME 1 eye trial.
Satish K. Garg, MD, University of Colorado Denver, will discuss the effects of glucagon-like peptide 1 (GLP-1) receptor agonists on diabetic retinopathy.
Register Today for the 85th Scientific Sessions
Join us in Chicago for the 85th Scientific Sessions, June 20–23, to learn about the latest advances in diabetes research, prevention, and care. Full in-person registration includes access to all of the valuable onsite content during the meeting and on-demand access to session recordings June 25–August 25.